The American College of Cardiology and Society for Cardiovascular Angiography (SCAI) and Interventions are just two of the medical societies concerned about this proposal. 

To limit any potential bias, the study's authors explored data from two different sources. 

Researchers tracked data from 500 participants who completed a web-based evaluation in their home.

The increasing popularity of TAVR appears to be the biggest reason for this shift.

Each company is believed to be in violation of the Federal Food, Drug and Cosmetic Act. They have 15 working days to respond. 

More research is still needed to find out why these differences exist, but the authors did offer some possible explanations. 

The medication was also associated with a reduced number of renal events. 

Four top leaders shared their best practices for rads who come across a significant finding they may have previously overlooked.